SPINSANTI, MARCO
 Distribuzione geografica
Continente #
NA - Nord America 395
EU - Europa 267
AS - Asia 207
AF - Africa 23
SA - Sud America 3
Totale 895
Nazione #
US - Stati Uniti d'America 395
VN - Vietnam 105
GB - Regno Unito 67
SE - Svezia 52
IT - Italia 45
CN - Cina 44
DE - Germania 36
SG - Singapore 30
IN - India 18
IE - Irlanda 15
FR - Francia 10
RU - Federazione Russa 10
BG - Bulgaria 7
CI - Costa d'Avorio 7
TG - Togo 7
EE - Estonia 6
ZA - Sudafrica 6
CH - Svizzera 4
BE - Belgio 3
FI - Finlandia 3
NG - Nigeria 3
PK - Pakistan 3
BR - Brasile 2
CZ - Repubblica Ceca 2
ID - Indonesia 2
IR - Iran 2
JO - Giordania 2
NL - Olanda 2
AT - Austria 1
CO - Colombia 1
GR - Grecia 1
HR - Croazia 1
IL - Israele 1
PL - Polonia 1
UA - Ucraina 1
Totale 895
Città #
Dong Ket 62
Southend 56
Fairfield 53
Chandler 50
Ann Arbor 29
Ashburn 25
Singapore 23
Seattle 22
Wilmington 20
Santa Clara 17
Dublin 15
Princeton 14
Woodbridge 14
Bologna 13
Cambridge 13
Houston 12
Beijing 9
Abidjan 7
Boardman 7
Bremen 7
Lomé 7
Sofia 7
Turin 7
Nanjing 6
Padova 6
Redmond 6
Westminster 6
London 5
Bern 4
New York 4
Abeokuta 3
Berlin 3
Brussels 3
Fremont 3
Hebei 3
Jinan 3
Lanzhou 3
Medford 3
Saint Petersburg 3
San Diego 3
Shenzhen 3
Amman 2
Andover 2
Baltimore 2
Gojra 2
Hefei 2
Helsinki 2
Hyderabad 2
Jakarta 2
Jiaxing 2
Lanciano 2
Los Angeles 2
Modena 2
Norwalk 2
Phoenix 2
Shenyang 2
Taiyuan 2
Athens 1
Cameri 1
Changsha 1
Chaoyang 1
Cormano 1
Dearborn 1
Des Moines 1
Falls Church 1
Florence 1
Frankfurt Am Main 1
Guangzhou 1
Hangzhou 1
Islamabad 1
Johannesburg 1
Lappeenranta 1
Leawood 1
Lincoln 1
Mannheim 1
Milan 1
Moscow 1
Negrar 1
North Bergen 1
Olalla 1
Rome 1
San Francisco 1
Santiago 1
Valbonne 1
Warsaw 1
Wenzhou 1
Zanjan 1
Zhengzhou 1
Totale 622
Nome #
Comparison of JAK2V617F-positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology 169
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 160
CIRCULATING PLATELET AND MEGAKARYOCYTE-DERIVED MICROPARTICLES OF JAK2V617F MUTATED PATIENTS WITH MYELOFIBROSIS ARE DISREGULATED: A NOVEL LIQUID BIOPSY TOOL OF RESPONSE TO RUXOLITINIB? 147
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 129
In Depth Analysis of the Helicobacter pylori cag Pathogenicity Island Transcriptional Responses 122
Biological model membranes for biosensors applications: preparation and characterization and sensing properties 105
Deconvolution of intergenic polymorphisms determining high expression of Factor H binding protein in meningococcus and their association with invasive disease 84
Totale 916
Categoria #
all - tutte 2.240
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.240


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020109 0 0 0 0 0 14 26 21 23 12 5 8
2020/2021175 16 7 3 1 2 3 0 7 8 1 14 113
2021/2022166 8 10 8 15 12 6 7 11 1 18 37 33
2022/2023203 16 31 11 32 6 18 6 11 35 10 18 9
2023/202445 4 7 3 5 3 12 1 2 1 4 2 1
2024/202586 9 12 17 9 32 7 0 0 0 0 0 0
Totale 916